The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to understand the patient and clinic visit characteristics that affect health outcomes for individuals with knee osteoarthritis (OA) pain using topical diclofenac gel. The main questions it aims to answer are: * What baseline patient characteristics predict response to topical diclofenac? * Does patient physiology during the study visit predict response to topical diclofenac? * Do study visit characteristics predict response to topical diclofenac? Participants will: * attend 2 study visits to complete study questionnaires and have blood drawn * apply topical diclofenac to their knee for 8 weeks * complete biweekly questions about knee pain and diclofenac use between study visits

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• English-speaking

• 50 years of age or older

• Radiographically confirmed knee OA of K/L grade 2 or higher within the past 2 years

• Knee pain at least 15 days/month.

• Average worst daily pain 3/10 or higher over a two-week period.

Locations
United States
California
University of California Davis Health
RECRUITING
Sacramento
Contact Information
Primary
Maya Porter
mtporter@ucdavis.edu
916-734-4216
Backup
Michelle Dossett, MD, PhD
mdossett@ucdavis.edu
916-734-5367
Time Frame
Start Date: 2025-01-29
Estimated Completion Date: 2028-01-27
Participants
Target number of participants: 220
Treatments
Experimental: Diclofenac
All study participants receiving topical diclofenac gel 1%. Participants will be instructed to apply 4 grams of the gel to the index knee at least once per day, and up to 4 times per day, for 8 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Aging (NIA), Beth Israel Deaconess Medical Center
Leads: University of California, Davis

This content was sourced from clinicaltrials.gov